2013 Annual Meeting | The Spectrum of Motor Neuron Disease

Date Saturday 03/16/13

Time 04:00 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jeffrey Rosenfeld, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should be able to: identify distinct clinical entities which are currently included under the diagnostic label of ALS; identify leading hypotheses (genetic and biochemical) on pathogenesis of motor neuron disease; correlate selective disease presentations with (the possibility of) individual pathogenic mechanisms; and appreciate the controversy of "lumping versus splitting" the spectrum of motor neuron disease.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
04:00 PM - 04:10 PM		Introduction and Overview Jeffrey Rosenfeld, MD, PhD, FAAN
04:10 PM - 04:30 PM		Clinical Variants Jeffrey Rosenfeld, MD, PhD, FAAN
04:30 PM - 05:00 PM		Genetic Variability Michael J. Strong, MD, FAAN
05:00 PM - 05:10 PM		Overview of Underlying Mechanisms Jeffrey Rosenfeld, MD, PhD, FAAN
05:10 PM - 05:35 PM		FTD Case Presentation and Discussion of the Spectrum of FTD Clinical and Biological Phenotypes Michael J. Strong, MD, FAAN
05:35 PM - 05:50 PM		Implications for Management and Trial Design Jeffrey Rosenfeld, MD, PhD, FAAN
05:50 PM - 06:00 PM		Summary and Questions

Faculty Disclosures
Jeffrey Rosenfeld, MD, PhD, FAAN	Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ML Biosolutions. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amylyx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Catalyst. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexion. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anelixis. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Strongbridge Pharma. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Rosenfeld has received research support from MT Pharma. The institution of Dr. Rosenfeld has received research support from Alexion. The institution of Dr. Rosenfeld has received research support from Healey ALS Trial Center Mass General.
Michael J. Strong, MD, FAAN	No disclosure on file

��ɫ��

��ɫ��